This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignee: Elan Pharmaceuticals, Inc.. Active years: 2003.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2003
Title: John R Forsayeth: Innovator in Potassium Channel Research
Introduction
John R Forsayeth is a notable inventor based in San Francisco, CA. He has made significant contributions to the field of biochemistry, particularly in the study of potassium channels. His work has implications for understanding various diseases and developing new therapeutic approaches.
Latest Patents
Forsayeth holds a patent for "Potassium channel subunit polypeptide and polynucleotide compositions and uses therefor." This invention provides novel potassium channel subunits, denoted as Kv-SL1 and Kv-SL2, collectively referred to as Kv-SL. The patent also includes polynucleotides that identify and encode these subunits. Additionally, it offers expression vectors and host cells that comprise the nucleic acid sequence encoding Kv-SL. The invention further encompasses antibodies of Kv-SL and methods for diagnosing and treating diseases associated with the expression of Kv-SL, along with screening assays utilizing the protein, nucleotide, and antibody compositions. Forsayeth has 1 patent to his name.
Career Highlights
Forsayeth is currently associated with Elan Pharmaceuticals, Inc., where he continues to advance his research in potassium channels. His work is pivotal in the development of new medical treatments and understanding the underlying mechanisms of various diseases.
Collaborations
Forsayeth has collaborated with notable colleagues, including Byron Zhao and Raymond A Chavez. Their combined expertise contributes to the innovative research environment at Elan Pharmaceuticals.
Conclusion
John R Forsayeth is a distinguished inventor whose work on potassium channel subunits has the potential to impact medical science significantly. His contributions to the field are invaluable, and his ongoing research promises to lead to further advancements in therapeutic applications.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile